We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Nanosponge Vaccine Protects Mice from MRSA Toxin

By LabMedica International staff writers
Posted on 10 Dec 2013
A novel vaccine based on "nanosponges" that sequester toxic, pore-forming toxoids—such as that produced by MRSA (methicylin resistant Staphylococcus aureus)—permits presentation of these toxins to immune system defensive cells without danger of damaging them.

It is not possible to deliver a native pore-forming toxin to immune cells without damaging the cells. More...
However, the heating or chemical processing required to neutralize the toxin can compromise the toxin's structural integrity and reduce the value of the vaccine.

To get around this problem, investigators at the University of California, San Diego (USA) developed "nanosponges.” These are biocompatible particles made of a polymer core wrapped in a red blood cell membrane. The red blood cell coating allows the nanosponge to incorporate and hold I alpha-hemolysin toxin without compromising the toxin’s structural integrity through heating or chemical processing. Despite being intact structurally, the trapped toxoid is rendered incapable of damaging other cells.

A paper published in the December 1, 2013, online edition of the journal Nature Nanotechnology presented results from experiments in which nanosponges loaded with toxoid were used to protect mice from MRSA infection. After one injection of the vaccine, 50% of the nanosponge-treated animals survived as compared to fewer than 10% of mice that had been vaccinated with heat-inactivated toxoid. An additional two booster shots increased the survival rate for the nanosponge-vaccinated animals to 100% compared to 90% for those vaccinated with the heat-treated toxin.

"The more you heat it, the safer the toxin is, but the more you heat it, the more you damage the structure of the protein," said senior author Dr. Liangfang Zhang, professor of nanoengineering at the University of California, San Diego. "And this structure is what the immune cell recognizes, and builds its antibodies against. Before this there was no way you could deliver a native toxin to the immune cells without damaging the cells, but this technology allows us to do this."

"The nanosponge vaccine was also able to completely prevent the toxin's damages in the skin, where MRSA infections frequently take place," said Dr. Zhang. "The particles work so beautifully that it might be possible to detain several toxins at once on them, creating one vaccine against many types of pore-forming toxins, from Staphylococcus to snake venom."

Related Links:

University of California, San Diego



New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Collection and Transport System
PurSafe Plus®
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.